Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

3
results for

"Hye Jin Cho"

Keywords

Publication year

"Hye Jin Cho"

Original Articles
Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer
Daeseong Kim, Nam Suk Sim, Seonjeong Woo, Min Hwan Kim, Choong-kun Lee, Seung Soo Hong, Sung Hyun Kim, Ho Kyoung Hwang, Chang Moo Kang, Woo Jung Lee, Jung Hyun Jo, Taek Chung, Sohyun Hwang, Beodeul Kang, Jung Sun Kim, Chang-Il Kwon, Sangwoo Kim, Hong Jae Chon, Chang Gon Kim, Young Nyun Park, Hye Jin Choi
Received September 9, 2025  Accepted December 24, 2025  Published online December 26, 2025  
DOI: https://doi.org/10.3350/cmh.2025.1019    [Accepted]
Background & Aims
Biliary tract cancer (BTC) is a rare malignancy with poor prognosis. We investigated genomic determinants of clinical benefit from gemcitabine, cisplatin, and nab-paclitaxel (GAP) versus gemcitabine and cisplatin (GC) in advanced BTC.
Methods
Clinical and genomic data using TruSight Oncology 500 were analyzed from patients treated with GAP (N=198) or GC (N=89) as first-line therapy.
Results
With a median follow-up of 33.0 months, GAP modestly improved progression-free survival (PFS) (hazard ratio [HR]=0.764, 95% confidence interval [CI]=0.591–0.989) without significant overall survival (OS) difference compared to GC. Genomic profiling revealed frequent alterations in TP53 (35.2%), KRAS (16.4%), SMAD4 (10.5%), and TNFRSF14 (10.5%), involving RTK/RAS (44.3%), TP53 (41.8%), and PI3K (20.2%) pathways. Single-gene mutations did not predict treatment benefit. However, pathway-level analysis identified PI3K pathway activation as significantly associated with inferior PFS (HR=2.148, 95% CI=1.478–3.124) and OS (HR=2.096, 95% CI=1.413–3.109) in patients receiving GAP, an effect not observed with GC. Importantly, GAP conferred clinical benefit only in patients without PI3K pathway activation, while no survival advantage was seen in those with such alterations (Pinteraction=0.023 for PFS, Pinteraction=0.003 for OS). Similar results were obtained in the independent validation cohort treated with GAP (N=103) or GC (N=64) for BTC.
Conclusion
Genomic profiling using next-generation sequencing identified PI3K pathway activation as key molecular determinant that differentiates patient outcomes between GAP and GC treatments in advanced BTC.
  • 544 View
  • 71 Download
Clinical features of acute viral hepatitis B in Korea: a multi-center study
Hye Jin Choi, Soon Young Ko, Won Hyeok Choe, Yeon Seok Seo, Ji Hoon Kim, Kwan Soo Byun, Young Seok Kim, Seung Up Kim, Soon Koo Baik, Jae Youn Cheong, Tae Yeob Kim, Oh Sang Kwon, Jeong Han Kim, Chang Hong Lee, So Young Kwon
Korean J Hepatol 2011;17(4):307-312.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.307
Background/Aims

The incidence of Hepatitis B has significantly declined since the introduction of an HBV vaccination program. The aim of this study was to investigate recent clinical features of acute viral hepatitis B (AVH-B) in Korea.

Methods

A total of 2241 patients with acute viral hepatitis were enrolled and their data were collected from nine medical-centers between January 2006 and December 2009.

Results

One hundred nineteen (5.3%) of the 2241 were diagnosed as AVH-B. Among 78 patients with AVH-B whose data were analyzed, 50 were male, and the mean age was 38.6 years. In an initial test, mean AST, ALT and total-bilirubin levels were 1296.2 IU/L, 2109.6 IU/L and 9.3 mg/dl, respectively. Positivity frequencies for HBeAg and anti-HBe were 55.1% and 67.9%, respectively, and the mean HBV DNA level was 5.2 log10 copies/ml. The mean length of hospitalization was 11.6 days. During follow-up, AST, ALT and total bilirubin levels were normalized or near-normalized in all patients without serious complications. Sixty-three of 66 (95.4%) patients showed HBsAg loss and 37 (56.1%) patients showed HBsAg seroconversion. Only 3 patients (4.5%) showed persistent hepatitis B viremia. There was no case of death or liver transplantation. Nine patients (11.3%) had received anti-viral agents and their clinical outcomes were not significantly different from those of patients treated without antiviral agents.

Conclusions

The prevalence of AVH-B among acute hepatitis patients is relatively low in Korea. AVH-B infection can be cured without complications in almost all patients, regardless of antiviral treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti‐HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure
    Robério Amorim de Almeida Pondé
    Microbiology and Immunology.2022; 66(1): 1.     CrossRef
  • Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China
    Yuting Wang, Ju-Fang Shi, Le Wang, Yongfeng Yan, Hongyu Yao, Min Dai, Taoyang Chen, Chunfeng Qu
    International Journal of Infectious Diseases.2019; 78: 130.     CrossRef
  • Antithrombin as a marker of severe acute hepatitis B
    Simona Arientová, O. Beran, P. Chalupa, M. Kořínková, M. Holub
    Indian Journal of Gastroenterology.2019; 38(2): 143.     CrossRef
  • The epidemiology of hepatitis B virus infection in Korea
    Sun Young Yim, Ji Hoon Kim
    The Korean Journal of Internal Medicine.2019; 34(5): 945.     CrossRef
  • The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
    Jung Hee Kim, Dong Hyun Sinn, Sung Wook Shin, Sung Ki Cho, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
    Clinical and Molecular Hepatology.2017; 23(1): 42.     CrossRef
  • Current status and strategies for hepatitis B control in Korea
    Eun Ju Cho, Sung Eun Kim, Ki Tae Suk, Jihyun An, Soung Won Jeong, Woo Jin Chung, Yoon Jun Kim
    Clinical and Molecular Hepatology.2017; 23(3): 205.     CrossRef
  • Pharmacological interventions for acute hepatitis B infection
    Konstantinos Mantzoukis, Manuel Rodríguez-Perálvarez, Elena Buzzetti, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis, Kurinchi Selvan Gurusamy
    Cochrane Database of Systematic Reviews.2017;[Epub]     CrossRef
  • Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013
    Yuan-Sheng Chen, Hui Zheng, Yan-Min Liu, Fu-Zhen Wang, Zhen-Hua Wu, Ning Miao, Xiao-Jin Sun, Guo-Min Zhang, Fu-Qiang Cui, Xiao-Feng Liang
    Human Vaccines & Immunotherapeutics.2016; : 1.     CrossRef
  • Prevention of hepatitis B virus-associated liver diseases by antiviral therapy
    Akinobu Tawada, Tatsuo Kanda, Fumio Imazeki, Osamu Yokosuka
    Hepatology International.2016; 10(4): 574.     CrossRef
  • Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection
    Nisha Sharma, Mitchell S. Cappell
    Digestive Diseases and Sciences.2015; 60(9): 2590.     CrossRef
  • Analysis of HBV genotype, drug resistant mutations, and pre‐core/basal core promoter mutations in Korean patients with acute hepatitis B
    Jong Ho Lee, Sun Pyo Hong, Eun Sun Jang, Sang Jong Park, Seong Gyu Hwang, Sook‐Kyoung Kang, Sook‐Hyang Jeong
    Journal of Medical Virology.2015; 87(6): 993.     CrossRef
  • An economic analysis of adult hepatitis B vaccination in China
    Hui Zheng, Fu-zhen Wang, Guo-min Zhang, Fu-qiang Cui, Zhen-hua Wu, Ning Miao, Xiao-jin Sun, Xiao-feng Liang, Li Li
    Vaccine.2015; 33(48): 6831.     CrossRef
  • Clinical Characteristics and Outcomes of Acute Hepatitis A in Korea: A Nationwide Multicenter Study
    So Young Kwon, Sang Hoon Park, Jong Eun Yeon, Sook Hyang Jeong, Oh Sang Kwon, Jin Woo Lee, Hong Soo Kim, Yeon Seok Seo, Young Seok Kim, Joo Hyun Sohn, Hyung Joon Yim, Jong Young Choi, Myung Seok Lee, Young Oh Kweon, Jae Youn Cheong, Haak Cheoul Kim, Heon
    Journal of Korean Medical Science.2014; 29(2): 248.     CrossRef
  • Association between apolipoprotein E genotype, chronic liver disease, and hepatitis B virus
    Seun Joo Ahn, Dong Kyu Kim, Soon Sun Kim, Chang Bum Bae, Hyo Jung Cho, Han Gyeol Kim, Young Jip Kim, Joo Ho Lee, Hyo Jin Lee, Mi Yeon Lee, Kee Bum Kim, Jin Hee Cho, Sung Won Cho, Jae Youn Cheong
    Clinical and Molecular Hepatology.2012; 18(3): 295.     CrossRef
  • 11,689 View
  • 81 Download
  • Crossref
Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels
Dong Jin Kim, Hyun Seok Kang, Hyuk Soon Choi, Hye Jin Cho, Eun Sun Kim, Bora Keum, Hyonggin An, Ji Hoon Kim, Yeon Seok Seo, Yong Sik Kim, Hyung Joon Yim, Yoon Tae Jeen, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
Korean J Hepatol 2011;17(2):130-138.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.130
Background/Aims

Several studies suggested that serum cystatin C (CysC) is more useful than serum creatinine (Cr) for the assessment of renal function in patients with liver cirrhosis. This study evaluated the clinical significance of CysC in patients with cirrhotic ascites and normal Cr level.

Methods

We enrolled patients with cirrhotic ascites and a normal serum Cr level (<1.2 mg/dL). GFR was measured by 99mTc-DTPA renal scan. Serum Cr, CysC, and Cr clearance (CCr) were measured on the same day. Significant renal impairment and severe renal impairment were defined as GFR <60 mL/min and GFR <30 mL/min, respectively.

Results

Eighty-nine patients with cirrhotic ascites were enrolled in the study (63 men and 26 women; age, 55±11 years). Forty-seven (52.8%) and 42 (47.2%) patients were in Child-Pugh grade B and C, respectively. Serum Cr and CysC levels and GFR were 0.8±0.2 mg/dL, 1.1±0.3 mg/L, and 73.4±25.5 mL/min, respectively. Significant and severe renal impairment were noted in 28 (31.5%) and 2 (2.2%) patients, respectively. GFR was well correlated with serum Cr, CysC, and e-GFRMDRD, while it was not correlated with e-GFRC&G. In multivariate analysis, only CysC was significantly correlated with GFR (β, 45.620; 95% CI, 23.042-68.198; P<0.001). Serum CysC level was the only independent predictor for significant renal impairment.

Conclusions

Significant renal dysfunction was not rare in patients with cirrhotic ascites, even their serum Cr level is normal. Serum CysC is a useful marker for detecting significant renal dysfunction in these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Diagnostic value of serum TGF-β1 and CysC in type 2 diabetic kidney disease: a cross-sectional study
    Yi Kang, Qian Jin, Mengqi Zhou, Huijuan Zheng, Xiaobin Li, Aoshuang Li, Jing Wei Zhou, Jie Lv, Yaoxian Wang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Zonula occludens 1 as a novel biomarker in decompensated alcoholic cirrhosis with hepatorenal syndrome
    Balasubramaniyan Vairappan, Raj Kumar, Mukta Wyawahare
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • Improved outcomes of kidney after liver transplantation after the implementation of the safety net policy
    Rose Mary Attieh, Ramez M. Ibrahim, Peter Ghali, Andrew Keaveny, Kristopher Croome, David Hodge, Launia White, Hani M. Wadei
    Liver Transplantation.2024; 30(6): 582.     CrossRef
  • The diagnostic and prognostic utility of serum cystatin C and angiopoietin 2 in patients with liver cirrhosis complicated by acute kidney injury
    Ahmed M. Abd El Wahab, Abeer Awadeen, Mostafa M. Mansour, Rasha Shemies
    Therapeutic Apheresis and Dialysis.2023; 27(3): 419.     CrossRef
  • Role of Novel Kidney Biomarkers in Patients With Cirrhosis and After Liver Transplantation
    Sumeet K. Asrani, Nagasri Shankar, Briget da Graca, Mitra K. Nadim, Andres Cardenas
    Liver Transplantation.2022; 28(3): 466.     CrossRef
  • Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients
    Fathia Elsayed Asal, Mohamed Yousef, Hend Atteya Abdelkhalek Abdraboh, Sherief Abd-Elsalam, Ahmed Abdelaziz Abdelaziz Shama, Mohamed Elbahnasawy, Mohammed H Elnaggar, Hesham Ahmed Alsrogy, Heba Elashry
    The Open Biomarkers Journal.2022;[Epub]     CrossRef
  • Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinine‐Based and Cystatin C–Based Equations: Systematic Review and Meta‐Analysis
    Prianka Singapura, Tsung‐Wei Ma, Naveed Sarmast, Stevan A. Gonzalez, François Durand, Rakhi Maiwall, Mitra K. Nadim, John Fullinwider, Giovanna Saracino, Claire Francoz, Rebecca Sartin, James F. Trotter, Sumeet K. Asrani
    Liver Transplantation.2021; 27(11): 1538.     CrossRef
  • Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure
    Praveen Jha, Ashish Kumar Jha, Vishwa Mohan Dayal, Sanjeev Kumar Jha, Amarendra Kumar
    Indian Journal of Gastroenterology.2021; 40(6): 563.     CrossRef
  • Serum cystatin C unmasks renal dysfunction in cirrhosis and performs better in estimation of glomerular filtration rate
    Balaraman Velayudham, RemiGeorge Thomas, C Vasudevan, RP Senthilkumar, Thirumalvalavan, Murugesan
    Saudi Journal of Kidney Diseases and Transplantation.2020; 31(6): 1320.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients
    Dong Wang, Jia-Fu Feng, An-Qun Wang, Yu-Wei Yang, Yun-Shuang Liu
    Medicine.2017; 96(20): e6949.     CrossRef
  • How to evaluate renal function in stable cirrhotic patients
    Florencia I. Aiello, Magdalena Bajo, Fernanda Marti, Carlos G. Musso
    Postgraduate Medicine.2017; 129(8): 866.     CrossRef
  • Appréciation du débit de filtration glomérulaire et de la dysfonction rénale chez le cirrhotique
    C. Mousseaux, A. Bouguerba, S. Ayed, J. Barchasz, M. Boukari, D. Goldgran-Toledano, C. Bornstain, F. Vincent
    Réanimation.2016; 25(S3): 137.     CrossRef
  • Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis
    Mahmoud Omar, Wael Abdel-Razek, Gamal Abo-Raia, Medhat Assem, Gasser El-Azab
    International Journal of Hepatology.2015; 2015: 1.     CrossRef
  • GFR Estimating Equations and Liver Disease
    Tomasz Beben, Dena E. Rifkin
    Advances in Chronic Kidney Disease.2015; 22(5): 337.     CrossRef
  • Prognostic value of serum cystatin C levels in cirrhotic patients with normal serum creatinine
    Bilyana Teneva, Emiliya Karaslavova
    Open Medicine.2014; 9(5): 625.     CrossRef
  • Update on Cystatin C: Incorporation Into Clinical Practice
    Michael G. Shlipak, Monica D. Mattes, Carmen A. Peralta
    American Journal of Kidney Diseases.2013; 62(3): 595.     CrossRef
  • Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation
    Jeffrey C Sirota, Angela Walcher, Sarah Faubel, Alkesh Jani, Kim McFann, Prasad Devarajan, Connie L Davis, Charles L Edelstein
    BMC Nephrology.2013;[Epub]     CrossRef
  • Impact of creatinine production on the agreement between glomerular filtration rate estimates using cystatin C-derived, and 4- and 6-variable Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equ
    Esperanza F. Hermida-Cadahia, Natalia Lampon, J. Carlos Tutor
    Upsala Journal of Medical Sciences.2012; 117(4): 402.     CrossRef
  • Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury
    W. Stephen Waring, Alasdair Moonie
    Clinical Toxicology.2011; 49(8): 720.     CrossRef
  • 12,545 View
  • 89 Download
  • Crossref